Molecular Partners shares surge 10.82% premarket as positive MP0712 clinical data supports U.S. Phase 1/2a trial for DLL3-targeted alpha therapy.

Molecular Partners surged 10.82% in premarket trading following the presentation of first-in-human imaging and dosimetry data for its DLL3-targeted Radio-DARPin candidate MP0712 at the TWC 2026 congress. The data demonstrated strong tumor uptake and favorable biodistribution in five patients, supporting the therapeutic potential of MP0712 for small cell lung cancer and neuroendocrine cancers. The results validated the company’s Radio-DARPin platform for delivering alpha-emitting isotopes to tumors with minimal healthy tissue exposure, accelerating the U.S. Phase 1/2a study (NCT07278479) with initial clinical data expected in 2026. A conference call featuring nuclear medicine expert Prof. Ken Herrmann further reinforced investor confidence in the program’s clinical and commercial potential.